ESSA Pharma Inc.
EPIX
$0.2456
-$0.0175-6.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.04M | 14.79M | 15.21M | 13.21M | 11.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.66M | 33.40M | 36.51M | 34.42M | 33.88M |
| Operating Income | -29.66M | -33.40M | -36.51M | -34.42M | -33.88M |
| Income Before Tax | -25.27M | -28.50M | -31.11M | -28.54M | -27.67M |
| Income Tax Expenses | -- | -- | -- | -- | 0.00 |
| Earnings from Continuing Operations | -25.27 | -28.50 | -31.11 | -28.54 | -27.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.27M | -28.50M | -31.11M | -28.54M | -27.67M |
| EBIT | -29.66M | -33.40M | -36.51M | -34.42M | -33.88M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.57 | -0.64 | -0.70 | -0.64 | -0.63 |
| Normalized Basic EPS | -0.35 | -0.40 | -0.44 | -0.40 | -0.39 |
| EPS Diluted | -0.57 | -0.64 | -0.70 | -0.64 | -0.63 |
| Normalized Diluted EPS | -0.35 | -0.40 | -0.44 | -0.40 | -0.39 |
| Average Basic Shares Outstanding | 177.53M | 177.51M | 177.36M | 177.10M | 176.82M |
| Average Diluted Shares Outstanding | 177.53M | 177.51M | 177.36M | 177.10M | 176.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |